British Journal of Clinical Pharmacology · 1989 · 45 citations · 15 references
MedicineNeurosciencePharmacotherapyClinical NeuroscienceEpilepsyNeuropharmacologyAntiepileptic PharmacotherapyAuditory Brainstem ResponsesAuditory Evoked PotentialsElectroencephalographyEvoked PotentialsVisual Evoked PotentialsAntiepileptic Clinical TrialsAuditory Evoked Potential AnalysisInterindividual Variability AnalysisPre-treatmentTreatment Outcomes In EpilepsyVigabatrin TherapyVisual Evoked Potential AnalysisVisually Evoked Potentials
1. Somatosensory (SEP) brainstem auditory (BAEP) and visual (VEP) evoked potentials were determined before and after add-on administration of vigabatrin (GVG) in patients with epilepsy. 2. At pre-treatment assessment SEP and BAEP parameters were usually found to be within normal limits, while P100 latencies of the VEP were abnormally prolonged in a considerable proportion of patients. 3. In a double-blind, placebo-controlled trial in 22 patients GVG (1-3 g day-1 stratified according to body weight) given for 7 weeks did not modify any of the evoked potential parameters evaluated. 4. Eighteen patients were evaluated prospectively at regular intervals during long-term GVG (2-4 g day-1) therapy with a mean follow up of 24 months (range 13-42 months). SEP, BAEP and especially VEP parameters showed some interindividual variability, but the within patient variation was relatively small. No consistent important changes were seen in association with GVG, although a possible trend towards a shortening of BAEP latencies and P100 latencies was observed. 5. The relevance of these findings with respect to GVG safety is discussed.
15
Evoked Potentials in Clinical Medicine
E.M. Sedgwick · Journal of Neurology Neurosurgery & Psychiatry · 1984 · 216 citations · Full text
Medicine, Neurology, Neuroscience +11
Vigabatrin in the Treatment of Epilepsy: A Double‐Blind, Placebo‐Controlled Study
A Tártara, Raffaele Manni, Carlo Andrea Galimberti et al. · Epilepsia · 1986 · 125 citations